10.1002/asia.201900306
Chemistry - An Asian Journal
COMMUNICATION
nitroaryl)methanols under light is described, in which C(sp3)-H
and N-H bonds are cleaved and C-N and N-N bonds are
constructed. This reaction proceeds at ambient temperature and
pressure under CO2 atmosphere using a variety of benzylamines
and alkylamines. This reaction is promoted by an ammonium
carbamate ([RNH3]+[OC(O)NHR]-) generated in situ from RNH2
and CO2 as a weak acid, and any other additives such as
transition metals, photocatalysts, acids or bases are not needed.
Furthermore, CO2 can be easily removed from the reaction
system and the present procedure is suitable for large scale
production. Some of these compounds synthesized by the
present method were found to exhibit potent anticancer activities,
which can lower the viability of cancerous cell line such as Hela,
MCF-7 and U87.
[6] For selected examples on synthetic routes for indazolones: a) A. Ilangovan;
P. Sakthivel; P. Sakthivel, Org. Chem. Front. 2016, 3, 1680; b) F. Sadri; A.
Ramazani; A. Massoudi; M. Khoobi; R. Tarasi; A. Shafiee; V. Azizkhani; L.
Dolatyari; S. W. Joo, Green. Chem. Lett. Rev. 2014, 7, 257; c) M. J. Kurth;
M. M. Olmstead; M. J. Haddadin, J. Org. Chem. 2005, 70, 1060; d) L. De
Luca; G. Giacomelli; S. Masala; A. Porcheddu, J. Org. Chem. 2003, 68,
4999; e) L.-J. Chen; L. T. Burka, Tetrahedron Lett. 1998, 39, 5351.
[7] During our work preparation, two similiar work were appearing, see: a) J. S.
Zhu; N. Kraemer; C. J. Li; M. J. Haddadin; M. J. Kurth, J. Org. Chem. 2018,
83, 15493; b) J. S. Zhu; N. Kraemer; M. E. Shatskikh; C. J. Li; J.-H. Son;
M. J. Haddadin; D. J. Tantillo; M. J. Kurth, Org. Lett. 2018, 20, 4736.
[8] For selected examples on CO2: a) X.-Y. Li; S.-S. Zheng; X.-F. Liu; Z.-W.
Yang; T.-Y. Tan; A. Yu; L.-N. He, ACS Sustainable Chem. Eng. 2018, 6,
8130; b) H. Rao; L. C. Schmidt; J. Bonin; M. Robert, Nature 2017, 548, 74;
c) Q.-W. Song; Z.-H. Zhou; L.-N. He, Green Chem. 2017, 19, 3707; d) X.-
F. Liu; X.-Y. Li; C. Qiao; H.-C. Fu; L.-N. He, Angew. Chem., Int. Ed. 2017,
56, 7425; Angew.Chem. 2017, 129, 7533; e) A. Banerjee; G. R. Dick; T.
Yoshino; M. W. Kanan, Nature 2016, 531, 215; f) S.-M. Lu; Z. Wang; J. Li;
J. Xiao; C. Li, Green Chem. 2016, 18, 4553; g) B. Yu; J.-N. Xie; C.-L. Zhong;
W. Li; L.-N. He, ACS Catalysis 2015, 5, 3940.
Acknowledgements
The authors thank the Natural Science Foundation of China
(21676076, 21725602, 21878071), Hu-Xiang High Talent of
Hunan Province (2018RS3042), and Recruitment Program for
Foreign Experts of China (WQ20164300353) for financial support.
[9] M. Kapoor; D. Liu; M. C. Young, J. Am. Chem. Soc. 2018, 140, 6818.
[10] For selected examples on C-N bond constructions: a) X. Yu; L. Gao; L. Jia;
Y. Yamamoto; M. Bao, J. Org. Chem. 2018, 83, 10352; b) Y. Pan; C. Chen;
X. Xu; H. Zhao; J. Han; H. Li; L. Xu; Q. Fan; J. Xiao, Green Chem. 2018,
20, 403; c) Z.-Z. Zhang; B. Liu; J.-W. Xu; S.-Y. Yan; B.-F. Shi, Org. Lett.
2016, 18, 1776; d) F.-J. Chen; G. Liao; X. Li; J. Wu; B.-F. Shi, Org. Lett.
2014, 16, 5644; e) S. Zhang; Y. Wang; X. Feng; M. Bao, J. Am. Chem. Soc.
2012, 134, 5492; f) Y. Minami; Y. Shiraishi; K. Yamada; T. Hiyama, J. Am.
Chem. Soc. 2012, 134, 6124.
Conflict of interest
The authors declare no conflict of interest.
Keywords: photocatalyst-free • metal-free • indazolones •
synthetic methods • anticancer
[11] For selected examples on N-N bond constructions: a) E. G. Abucayon; R.
L. Khade; D. R. Powell; Y. Zhang; G. B. Richter-Addo, J. Am. Chem. Soc.
2018, 140, 4204; b) K.-K. A. Wang; T. L. Ng; P. Wang; Z. Huang; E. P.
Balskus; W. A. van der Donk, Nat. Commun. 2018, 9, 3687.
[1] For selected examples on indazolones attract attention by their biological
activities and their heterocyclic skeleton: a) Z. Wang; Z. Yin; F. Zhu; Y. Li;
X.-F. Wu, ChemCatChem 2017, 9, 3637; b) E. Schütznerová; V. Krchňák,
J. Org. Chem. 2016, 81, 3585; c) P. Gonzalez-Naranjo; N. Perez-Macias;
N. E. Campillo; C. Perez; V. J. Aran; R. Giron; E. Sanchez-Robles; M. I.
Martin; M. Gomez-Canas; M. Garcia-Arencibia; J. Fernandez-Ruiz; J. A.
Paez, Eur. J. Med. Chem. 2014, 73, 56; d) Y. Tominari; K. Ono; S.
Matsumoto; T. Katoh; A. Hasuoka; S. Imamura, PCT Int. Appl.,
2013051632 A1, 2013; e) M. G. Hahn; E.-M. Becker; A. Knorr; D.
Schneider; J.-P. Stasch; K.-H. Schlemmer; F. Wunder; F. Stoll; S.
Heitmeier; K. Muenter, PCT Int. Appl., 2009127338 A1, 2009; f) J. S.
Oakdale; D. M. Solano; J. C. Fettinger; M. J. Haddadin; M. J. Kurth, Org.
Lett. 2009, 11, 2760; g) S. D. Wyrick; P. J. Voorstad; G. Cocolas; I. H. Hall,
J. Med. Chem. 1984, 27, 768.
[12] Copies of crystallographic data (CCDC 1848192 (3a)) can be obtained free
of charge from the Cambridge Crystallographic Data Centre via
[13] For selected examples on tryptamine derivatives possessing high potential
for the treatment of various diseases: a) R. F. Salikov; A. Y. Belyy; N. S.
Khusnutdinova; Y. V. Vakhitova; Y. V. Tomilov, Bioorg. Med. Chem. Lett.
2015, 25, 3597; b) T. Maurer; L. S. Garrenton; A. Oh; K. Pitts; D. J.
Anderson; N. J. Skelton; B. P. Fauber; B. Pan; S. Malek; D. Stokoe; M. J.
C. Ludlam; K. K. Bowman; J. Wu; A. M. Giannetti; M. A. Starovasnik; I.
Mellman; P. K. Jackson; J. Rudolph; W. Wang; G. Fang, Proc. Natl. Acad.
Sci. USA 2012, 109, 5299; c) B. Beck; S. Hess; A. Dömling, Bioorg. Med.
Chem. Lett. 2000, 10, 1701.
[14] For selected examples on comparison with the reported method: A.
Cappelli; C. Nannicini; A. Gallelli; G. Giuliani; S. Valenti; G. l. P. Mohr; M.
Anzini; L. Mennuni; F. Ferrari; G. Caselli; A. Giordani; W. Peris; F.
Makovec; G. Giorgi; S. Vomero, J. Med. Chem. 2008, 51, 2137.
[2] For selected examples on indazolones with anti-inflammatory: a) S. A. M.
El-Hawash; E.-S. A. M. Badawey; I. M. El-Ashmawey, Eur. J. Med. Chem.
2006, 41, 155; b) K. A. M. Abouzid; H. S. El-Abhar, Arch. Pharm. Res. 2003,
26, 1; c) E. Tse; L. Butner; Y. Huang; I. H. Hall, Arch. Phnrm. Phartn. Med.
Chem. 1996, 329, 35.
[15] For selected examples on previous work about indazolones mechanism: a)
S. W. Park; H. Choi; J.-h. Lee; Y.-J. Lee; J.-M. Ku; S. Y. Lee; T.-g. Nam,
Arch. Pharm. Res. 2016, 39, 302; b) M. Tsujii; M. Sonoda; S. Tanimori, J.
Org. Chem. 2016, 81, 6766; c) G. Dou; D. Shi, J. Comb. Chem. 2009, 11,
1073; d) M. Krishnamurthy; S. K. Dogra, Chem. Phys. 1986, 103, 325.
[16] For selected examples on intermediate B formation: a) B. Avila; M. H. El-
Dakdouki; M. Z. Nazer; J. G. Harrison; D. J. Tantillo; M. J. Haddadin; M. J.
Kurth, Tetrahedron Lett. 2012, 53, 6475; c) R. T. Cummings; G. A. Krafft,
Tetrahedron Lett. 1988, 29, 65.
[3] P. Bruneau; C. Delvare; M. P. Edwards; R. M. McMillan, J. Med. Chem.
1991, 34, 1028.
[4] I. H. Hall; W. L. Williams; S. D. Wyrick; P. J. Voorstad, J. Pharm. Sci. 1984,
73, 1788.
[5] For selected examples on antitumor agents in human tumor cells: a) C.
Pérez-Medina; C. López; M. Pilar Cabildo; R. M. Claramunt; M. Carmen
Torralba; M. Rosario Torres; I. Alkorta; J. Elguero, J. Mol. Struct. 2012,
1022, 139; b) I. H. Hall; O. T. Wong; E. S. Hall; L. K. Chen, Anti-Cancer
Drugs 1993, 4, 389.
This article is protected by copyright. All rights reserved.